Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2, New England Journal of Medicine, vol.344, issue.11, pp.783-92, 2001. ,
DOI : 10.1056/NEJM200103153441101
Adjuvant Trastuzumab in HER2-Positive Breast Cancer, New England Journal of Medicine, vol.365, issue.14, pp.1273-83, 2011. ,
DOI : 10.1056/NEJMoa0910383
URL : http://europepmc.org/articles/pmc3268553?pdf=render
Gefitinib or Carboplatin???Paclitaxel in Pulmonary Adenocarcinoma, New England Journal of Medicine, vol.361, issue.10, pp.947-57, 2009. ,
DOI : 10.1056/NEJMoa0810699
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation, New England Journal of Medicine, vol.364, issue.26, pp.2507-2523, 2011. ,
DOI : 10.1056/NEJMoa1103782
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction, Cell, vol.136, issue.5, pp.823-860, 2009. ,
DOI : 10.1016/j.cell.2009.02.024
URL : https://doi.org/10.1016/j.cell.2009.08.006
Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling, Oncogene, vol.30, issue.45, pp.4567-77, 2011. ,
DOI : 10.1158/0008-5472.CAN-08-0632
URL : http://www.nature.com/onc/journal/v30/n45/pdf/onc2011164a.pdf
Converting Cancer Therapies into Cures: Lessons from Infectious Diseases, Cell, vol.148, issue.6, pp.1089-98, 2012. ,
DOI : 10.1016/j.cell.2012.02.015
URL : https://doi.org/10.1016/j.cell.2012.02.015
Targeting RAS signalling pathways in cancer therapy, Nature Reviews Cancer, vol.61, issue.1, pp.11-22, 2003. ,
DOI : 10.1038/356397a0
mTOR Signaling in Growth Control and Disease, Cell, vol.149, issue.2, pp.274-93, 2012. ,
DOI : 10.1016/j.cell.2012.03.017
URL : https://doi.org/10.1016/j.cell.2012.03.017
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer, Journal of Clinical Investigation, vol.118, pp.3065-74, 2008. ,
DOI : 10.1172/JCI34739DS1
mTOR inhibitors: rationale and importance to inhibiting these pathways in human health, Oncotarget, vol.2, pp.135-64, 2011. ,
DOI : 10.18632/oncotarget.240
URL : http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=240&path%5B%5D=353
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers, Nature Medicine, vol.13, issue.12, pp.1351-1357, 2008. ,
DOI : 10.1128/MCB.18.3.1379
URL : http://europepmc.org/articles/pmc2683415?pdf=render
Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas, Clinical Cancer Research, vol.18, issue.9, pp.2515-2540, 2012. ,
DOI : 10.1158/1078-0432.CCR-11-2683
Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer, Cancer Treatment Reviews, vol.39, issue.8, pp.935-981, 2013. ,
DOI : 10.1016/j.ctrv.2013.03.009
A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors, Clinical Cancer Research, vol.21, issue.4, pp.730-738, 2015. ,
DOI : 10.1158/1078-0432.CCR-14-1814
Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK, Clinical Cancer Research, vol.21, issue.4, pp.739-787, 2015. ,
DOI : 10.1158/1078-0432.CCR-14-1901
URL : http://clincancerres.aacrjournals.org/content/clincanres/21/4/739.full.pdf
A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors, Annals of Oncology, vol.26, issue.1, pp.58-64, 2015. ,
DOI : 10.1634/theoncologist.2011-0111
The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer, Clinical Cancer Research, vol.18, issue.8, pp.2316-2341, 2012. ,
DOI : 10.1158/1078-0432.CCR-11-2381
-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib, Cancer Discovery, vol.2, issue.3, pp.227-262, 2012. ,
DOI : 10.1158/2159-8290.CD-11-0341
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR, Nature, vol.15, issue.7388, pp.100-103, 2012. ,
DOI : 10.1016/j.ccr.2009.02.023
URL : https://iris.unito.it/retrieve/handle/2318/126889/19515/Prahallad_AuthorManuscript.pdf
Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer, Cell, vol.149, issue.2, pp.307-328, 2012. ,
DOI : 10.1016/j.cell.2012.02.053
Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks, Cell, vol.149, issue.4, pp.780-94, 2012. ,
DOI : 10.1016/j.cell.2012.03.031
URL : https://doi.org/10.1016/j.cell.2012.03.031
Sorafenib Overcomes Irinotecan Resistance in Colorectal Cancer by Inhibiting the ABCG2 Drug-Efflux Pump, Molecular Cancer Therapeutics, vol.12, issue.10, pp.2121-2155, 2013. ,
DOI : 10.1158/1535-7163.MCT-12-0966
URL : https://hal.archives-ouvertes.fr/inserm-00861055
New Topoisomerase I mutations are associated with resistance to camptothecin, Molecular Cancer, vol.10, issue.1, p.64, 2011. ,
DOI : 10.1016/j.jmb.2004.03.077
URL : https://hal.archives-ouvertes.fr/inserm-00602236
The search for synergy: a critical review from a response surface perspective, Pharmacol Rev, vol.47, pp.331-85, 1995. ,
Chemical combination effects predict connectivity in biological systems, Molecular Systems Biology, vol.12, p.80, 2007. ,
DOI : 10.1042/bj3120145
Combination chemical genetics, Nature Chemical Biology, vol.89, issue.11, pp.674-81, 2008. ,
DOI : 10.1021/ci00060a003
Synergistic drug combinations tend to improve therapeutically relevant selectivity, Nature Biotechnology, vol.6, issue.7, pp.659-66, 2009. ,
DOI : 10.1016/S0022-5193(85)80176-4
Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer, Cancer Cell, vol.19, issue.5, pp.575-86, 2011. ,
DOI : 10.1016/j.ccr.2011.04.008
URL : https://doi.org/10.1016/j.ccr.2011.04.008